[Clinical evaluation of the therapeutic value of barbexaclone including determination of plasma levels of the barbiturate].
The results of the use of barbexaclone (ciclo-hexil-aminopropan) in association with fenil-etil-barbiturate, as a single anticonvulsant drug in a clinical and therapeutic trial are reported. Seventy patients, 36 women and 34 men, 52 children and 18 adults, all of them with two or more epileptic grand-mal seizures at the beginning of treatment, were selected. In 53 patients a complete 18 months follow-up observation was performed. In this group of patients, 96% of them were free of seizures during the observation time. In 20 patients the barbiturate plasma concentration was measured. For these patients, the effectiveness of the treatment was up to 89%, in terms of complete control of convulsive crises. The measurements of the plasma level of anticonvulsants has shown to be most useful and a safe therapeutic guide in the treatment of epilepsies.
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004830:Epilepsy, Tonic-Clonic / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D011437:Propylamines / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use
D000927:Anticonvulsants; D011437:Propylamines; C011019:barbexaclone; D010634:Phenobarbital
Avaliaçao clínica do valor terapêutico do barbexaclone incluindo determinação de níveis plasmáticos do barbitúrico.